Figure 3.
A patient with a persistent pigment epithelial detachment (PED) and SRF despite 45 prior ranibizumab injections over the prior 50 months, was transitioned to aflibercept. Following 12 monthly aflibercept injections, there was resolution of the PED and SRF on SD-OCT. CFT improved from 419 to 207 μm and macular volume reduced from 8.92 to 8.94 mm3. Visual acuity was preserved at 20/60.